Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MDGL 
Madrigal Pharmaceuticals Inc (MDGL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: MDGL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $481.85
1 Year Target Price $481.85
| 10 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -23.01% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.52B USD | Price to earnings Ratio - | 1Y Target Price 481.85 |
Price to earnings Ratio - | 1Y Target Price 481.85 | ||
Volume (30-day avg) 15 | Beta -1.02 | 52 Weeks Range 200.63 - 457.16 | Updated Date 09/17/2025 |
52 Weeks Range 200.63 - 457.16 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.64 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -54.68% | Operating Margin (TTM) -22.18% |
Management Effectiveness
Return on Assets (TTM) -18.31% | Return on Equity (TTM) -36.3% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8845448428 | Price to Sales(TTM) 18.46 |
Enterprise Value 8845448428 | Price to Sales(TTM) 18.46 | ||
Enterprise Value to Revenue 17.16 | Enterprise Value to EBITDA -8.32 | Shares Outstanding 22289000 | Shares Floating 10975779 |
Shares Outstanding 22289000 | Shares Floating 10975779 | ||
Percent Insiders 7.7 | Percent Institutions 107.93 |
Upturn AI SWOT
Madrigal Pharmaceuticals Inc
Company Overview
History and Background
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH). Founded in 2006, it has primarily focused on targeting the thyroid hormone receptor (THR) beta pathway to treat liver and cardiometabolic diseases. The company's focus is on the development of resmetirom.
Core Business Areas
- NASH Drug Development: Madrigal focuses on the research, development, and commercialization of therapeutics for NASH and other liver-related diseases.
Leadership and Structure
Bill Sibold is the Chief Executive Officer. The company has a structured management team overseeing R&D, clinical development, and commercialization efforts.
Top Products and Market Share
Key Offerings
- Resmetirom (REZDIFFRA): Resmetirom is an oral, liver-directed thyroid hormone receptor (THR)-u03b2 selective agonist designed to improve outcomes for patients with NASH. It has received accelerated approval from the FDA. Market share is nascent as the drug is newly launched. Competitors include Viking Therapeutics (VKTR) (in development).
Market Dynamics
Industry Overview
The NASH market is a large and growing market with unmet medical needs. There is a race to develop effective therapies for the disease which is characterized by liver inflammation and fibrosis.
Positioning
Madrigal is positioned as a leader in the NASH space with the first FDA-approved therapy. Their competitive advantage comes from their first-mover status with resmetirom.
Total Addressable Market (TAM)
The NASH market is estimated to be multi-billion dollar market. Madrigal is poised to capture a significant share of the TAM with resmetirom, given its first to market advantage. Estimates range from $35-$50 Billion.
Upturn SWOT Analysis
Strengths
- First FDA-approved NASH therapy (Resmetirom)
- Strong clinical data supporting Resmetirom's efficacy
- Experienced management team
Weaknesses
- Reliance on a single product (Resmetirom)
- Potential for competition from other NASH therapies in development
- Uncertainty regarding long-term market adoption of Resmetirom
Opportunities
- Expanding Resmetirom's label to include earlier stages of NASH
- Developing combination therapies with Resmetirom
- Partnering with other companies to expand Resmetirom's market reach
Threats
- Competition from other NASH therapies
- Regulatory setbacks
- Pricing pressure
Competitors and Market Share
Key Competitors
- Viking Therapeutics (VKTR)
- Intercept Pharmaceuticals (ICPT)
Competitive Landscape
Madrigal's advantage is first-mover status. Viking Therapeutics is a potential competitor with promising data. Intercept's experience with OCA gives them some edge.
Growth Trajectory and Initiatives
Historical Growth: Historical growth primarily driven by clinical trial progress and market anticipation of NASH therapies.
Future Projections: Future growth is tied to Resmetirom sales and market penetration. Analyst estimates vary widely based on adoption rates.
Recent Initiatives: Recent initiatives include FDA approval of Resmetirom, commercial launch preparations, and continued clinical development efforts.
Summary
Madrigal is a leader in the NASH space due to receiving the first FDA approval. While this represents a significant milestone, they have to contend with larger competitors who are quickly advancing their own therapies. The firm's success hinges on Resmetirom's market penetration and on managing competitive pressures. The large, unmet market need represents significant opportunity, as well as the expansion to earlier stage NASH.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Press Releases
- FDA Website
Disclaimers:
The data provided is for informational purposes only and should not be construed as investment advice. Market share data is based on current available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Madrigal Pharmaceuticals Inc
Exchange NASDAQ | Headquaters West Conshohocken, PA, United States | ||
IPO Launch date 2007-02-06 | CEO, President & Director Mr. William J. Sibold | ||
Sector Healthcare | Industry Biotechnology | Full time employees 528 | Website https://www.madrigalpharma.com |
Full time employees 528 | Website https://www.madrigalpharma.com | ||
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.